文献速递关节外科创伤骨科

阿司匹林在假体周围感染翻修膝关节置换术后静脉血栓预防中优于低分子肝素

Aspirin Is Associated With Improved Thromboprophylaxis Versus Low-Molecular-Weight Heparin Following Revision Knee Arthroplasty for Periprosthetic Joint Infection.
PubMed 文献 · J Arthroplasty · 2026-03-03

本研究基于2016至2023年全国数据库,比较阿司匹林与低分子肝素在因假体周围感染行首次翻修全膝关节置换术后静脉血栓栓塞预防中的效果。倾向评分匹配后纳入10,472例患者(每组5,236例),阿司匹林组VTE发生率(1.0% vs 1.6%,P=0.002)和术后输血率(6.0% vs 8.2%,P<0.001)均显著低于低分子肝素组。

要点

  • 阿司匹林组VTE发生率1.0%,低于低分子肝素组的1.6%(P=0.002)。
  • 阿司匹林组术后输血率6.0%,低于低分子肝素组的8.2%(P<0.001)。
  • 对于无VTE病史的假体周围感染翻修膝关节置换患者,阿司匹林是安全有效的预防选择。

核心结论

  • 在无VTE病史的假体周围感染翻修全膝关节置换患者中,阿司匹林与较低的VTE和输血率相关。
  • 阿司匹林似乎是该人群VTE化学预防的安全有效选择。

研究设计与样本

  • 回顾性队列研究,查询2016至2023年大型全国数据库。
  • 纳入因膝关节假体周围感染行抗生素骨水泥间隔器置入的患者,术后第一天接受阿司匹林或低分子肝素者。
  • 排除使用其他预防药物或有VTE病史的患者。
  • 采用倾向评分匹配1:1匹配10,472例患者(5,236:5,236),协变量标准化均数差<0.10。
  • 两组平均年龄66岁,平均Charlson合并症指数3.2;阿司匹林组61.2%、低分子肝素组60.3%使用氨甲环酸。

主要发现

  • 阿司匹林组VTE发生率1.0%,低分子肝素组1.6%(P=0.002;调整比值比=0.6,95%置信区间=0.4至0.9)。
  • 阿司匹林组术后输血率6.0%,低分子肝素组8.2%(P<0.001;调整比值比=0.8,95%置信区间=0.6至0.9)。

临床怎么用

  • 对于无VTE病史的假体周围感染翻修全膝关节置换患者,可考虑使用阿司匹林作为VTE化学预防。
  • 阿司匹林与较低的VTE和输血率相关,支持其在该人群中的安全有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is no consensus regarding the optimal venous thromboembolism (VTE) chemoprophylaxis agent following surgery for periprosthetic joint infection (PJI). Aspirin (ASA) and low-molecular-weight heparin (LMWH) are two commonly used agents; however, efficacy data in this population is lacking. This study compared ASA to LMWH among patients undergoing first-stage revision total knee arthroplasty for PJI. METHODS: A large national database was queried from 2016 to 2023. Patients undergoing antibiotic spacer placement for a knee PJI were identified and divided into those who received either ASA or LMWH on postoperative day one. Patients taking other prophylactic agents or those who had a VTE history were excluded. Propensity score matching was used to balance cohorts. There were 10,472 patients 1:1 matched (5,236:5,236) based on VTE prophylaxis type and were well balanced for covariates (standardized mean difference < 0.10). Both cohorts had an average age of 66 years and an average Charlson comorbidity index of 3.2. Tranexamic acid was used in 61.2% of the ASA cohort and 60.3% of the LMWH cohort. To account for residual confounding, multivariable logistic regression models were used to assess our outcomes of VTE and postoperative transfusion. RESULTS: The ASA patients had lower rates of VTE (1.0 versus 1.6%, P = 0.002; adjusted odds ratio = 0.6, 95% confidence interval = 0.4 to 0.9). Postoperative transfusion rates were significantly lower in the ASA cohort (6.0 versus 8.2%, P < 0.001; adjusted odds ratio = 0.8, 95% confidence interval = 0.6 to 0.9). DISCUSSION: The use of ASA was associated with lower rates of VTE and transfusion compared to LMWH among patients who did not have a VTE history undergoing revision total knee arthroplasty for PJI. The use of ASA appears to be a safe and effective option for VTE chemoprophylaxis in this patient population.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Wier J, Kumaran P, Telang SS, et al. Aspirin Is Associated With Improved Thromboprophylaxis Versus Low-Molecular-Weight Heparin Following Revision Knee Arthroplasty for Periprosthetic Joint Infection. J Arthroplasty. 2026. PMID: 41786256. doi:10.1016/j.arth.2026.02.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。